Evidence map›Paper›PMID 34318893›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Growth Hormone Receptor (GHR) 6Ω Pseudoexon Activation: a Novel Cause of Severe Growth Hormone Insensitivity.

Emily Cottrell, Avinaash Maharaj, Jack Williams, Sumana Chatterjee, Grazia Cirillo, Emanuele Miraglia Del Giudice, Adalgisa Festa, Stefania Palumbo, Donatella Capalbo, Mariacarolina Salerno and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Emily CottrellCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0001-6773-6547
Avinaash MaharajCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0001-8051-3866
Jack WilliamsCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0002-1289-6671
Sumana ChatterjeeCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0001-5273-0046
Grazia CirilloStudies of Campania Luigi Vanvitelli, Department of Woman, Child, General and Specialized Surgery.ORCID 0000-0002-7823-972X
Emanuele Miraglia Del GiudiceStudies of Campania Luigi Vanvitelli, Department of Woman, Child, General and Specialized Surgery.ORCID 0000-0002-9410-5393
Adalgisa FestaStudies of Campania Luigi Vanvitelli, Department of Woman, Child, General and Specialized Surgery.ORCID 0000-0002-6747-445X
Stefania PalumboStudies of Campania Luigi Vanvitelli, Department of Woman, Child, General and Specialized Surgery.ORCID 0000-0002-8084-9818
Donatella CapalboFederico II University Hospital: Azienda Ospedaliera Universitaria Federico II.ORCID 0000-0003-3312-8628
Mariacarolina SalernoUniversity of Naples Federico II Department of Translational Medical Sciences: Universita degli Studi di Napoli Federico II Dipartimento di Scienze Mediche Traslazionali.ORCID 0000-0003-1310-3300
Claudio PignataUniversity of Naples Federico II Department of Translational Medical Sciences: Universita degli Studi di Napoli Federico II Dipartimento di Scienze Mediche Traslazionali.ORCID 0000-0003-1568-9843
Martin O SavageCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0001-7902-3376
Katharina SchilbachLMU Klinikum, Medizinische Klinik und Poliklinik IV, München.ORCID 0000-0002-8667-0296
Martin BidlingmaierLMU Klinikum, Medizinische Klinik und Poliklinik IV, München.
Vivian HwaChildrens Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID 0000-0003-0517-9049
Louise A MetherellCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0002-0530-3524
Anna GrandoneStudies of Campania Luigi Vanvitelli, Department of Woman, Child, General and Specialized Surgery.ORCID 0000-0002-6343-4768
Helen L StorrCentre for Endocrinology, William Harvey Research Institute: Barts and The London School of Medicine and Dentistry William Harvey Research Institute.ORCID 0000-0002-9963-1931
William Harvey Research Institute · GBUniversity of Campania "Luigi Vanvitelli" · ITLMU Klinikum · DEUniversity of Naples Federico II · ITCincinnati Children's Hospital Medical Center · USFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSevere forms of growth hormone insensitivity (GHI) are characterized by extreme short stature, dysmorphism, and metabolic anomalies.

objectiveThis work aims to identify the genetic cause of growth failure in 3 "classical" GHI individuals.

methodsA novel intronic growth hormone receptor gene (GHR) variant was identified, and in vitro splicing assays confirmed aberrant splicing. A 6Ω pseudoexon GHR vector and patient fibroblast analysis assessed the consequences of the novel pseudoexon inclusion and the impact on GHR function.

resultsWe identified a novel homozygous intronic GHR variant (g.5:42700940T > G, c.618+836T > G), 44 bp downstream of the previously recognized intronic 6Ψ GHR pseudoexon mutation in the index patient. Two siblings also harbored the novel intronic 6Ω pseudoexon GHR variant in compound heterozygosity with the known GHR c.181C > T (R43X) mutation. In vitro splicing analysis confirmed inclusion of a 151-bp mutant 6Ω pseudoexon not identified in wild-type constructs. Inclusion of the 6Ω pseudoexon causes a frameshift resulting in a nonfunctional truncated GHR lacking the transmembrane and intracellular domains. The truncated 6Ω pseudoexon protein demonstrated extracellular accumulation and diminished activation of STAT5B signaling following GH stimulation.

conclusionNovel GHR 6Ω pseudoexon inclusion results in loss of GHR function consistent with a severe GHI phenotype. This represents a novel mechanism of Laron syndrome and is the first deep intronic variant identified causing severe postnatal growth failure. The 2 kindreds originate from the same town in Campania, Southern Italy, implying common ancestry. Our findings highlight the importance of studying variation in deep intronic regions as a cause of monogenic disorders.

Indexed as

GHR 6Ω pseudoexongrowth hormone insensitivitysevere primary IGF-I deficiencyShort stature

Identifiers

PMID34318893
PMCPMC8684449
OpenAlexW3186841565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.